CG Oncology, Inc. financial data

Symbol
CGON on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
400 Spectrum Center Drive, Suite 2040, Irvine, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67.1M shares
Common Stock, Shares, Outstanding 66.7M shares
Common Stock, Value, Issued 7K USD
Weighted Average Number of Shares Outstanding, Basic 66.6M shares +1601%
Weighted Average Number of Shares Outstanding, Diluted 66.6M shares +1601%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18.5M USD +87.9%
General and Administrative Expense 7.49M USD +200%
Operating Income (Loss) -25.9M USD -110%
Nonoperating Income (Expense) 6.95M USD +875%
Net Income (Loss) Attributable to Parent -18.9M USD -62.8%
Earnings Per Share, Basic -0.28 USD/shares +92.9%
Earnings Per Share, Diluted -0.28 USD/shares +92.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.2M USD
Marketable Securities, Current 528M USD
Assets, Current 564M USD
Property, Plant and Equipment, Net 84K USD
Operating Lease, Right-of-Use Asset 329K USD
Other Assets, Noncurrent 53K USD
Assets 564M USD
Accounts Payable, Current 4.49M USD
Liabilities, Current 11.9M USD
Operating Lease, Liability, Noncurrent 118K USD
Liabilities 12M USD
Retained Earnings (Accumulated Deficit) -166M USD
Stockholders' Equity Attributable to Parent 552M USD
Liabilities and Equity 564M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26M USD -226%
Net Cash Provided by (Used in) Financing Activities 403M USD
Net Cash Provided by (Used in) Investing Activities -307M USD -291%
Common Stock, Shares Authorized 700M shares
Common Stock, Shares, Issued 66.7M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 69.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 25.2M USD -67.8%
Operating Lease, Liability 355K USD
Payments to Acquire Property, Plant, and Equipment 12K USD
Lessee, Operating Lease, Liability, to be Paid 359K USD
Operating Lease, Liability, Current 237K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 52K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 187K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4K USD
Operating Lease, Payments 45K USD 0%
Additional Paid in Capital 718M USD
Depreciation, Depletion and Amortization 4K USD 0%
Share-based Payment Arrangement, Expense 2.25M USD +1169%